165 related articles for article (PubMed ID: 9190837)
1. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
Li P; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 1997 Jun; 281(3):1065-70. PubMed ID: 9190837
[TBL] [Abstract][Full Text] [Related]
2. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
Li P; Ferrario CM; Brosnihan KB
J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
[TBL] [Abstract][Full Text] [Related]
3. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
J Pharmacol Exp Ther; 1994 Feb; 268(2):747-52. PubMed ID: 8113986
[TBL] [Abstract][Full Text] [Related]
5. Effects of losartan on contractile responses of conductance and resistance arteries from rats.
Corriu C; Bernard S; Schott C; Stoclet JC
J Cardiovasc Pharmacol; 1995 Nov; 26(5):688-92. PubMed ID: 8637181
[TBL] [Abstract][Full Text] [Related]
6. [Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].
Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
Arch Mal Coeur Vaiss; 1994 Aug; 87(8):971-4. PubMed ID: 7755474
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
8. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein.
Tripodi F; Stanke-Labesque F; Devillier P; Chavanon O; Sessa C; Bessard G
J Cardiovasc Pharmacol; 1999 Nov; 34(5):734-40. PubMed ID: 10547091
[TBL] [Abstract][Full Text] [Related]
10. Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Hakim A; Stanke-Labesque F; Hoffmann P; Sessa C; Caron F; Cracowski JL; Bessard G
J Cardiovasc Pharmacol; 2003 Jul; 42(1):42-7. PubMed ID: 12827025
[TBL] [Abstract][Full Text] [Related]
11. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
Fukuhara M; Neves LA; Li P; Diz DI; Ferrario CM; Brosnihan KB
J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
Schwemmer M; Sommer O; Bassenge E
Cardiovasc Drugs Ther; 2001 Jul; 15(4):301-7. PubMed ID: 11800413
[TBL] [Abstract][Full Text] [Related]
13. AT1 and TxA2/PGH2 receptors maintain hypertension throughout 2K,1C Goldblatt hypertension in the rat.
Wilcox CS; Cardozo J; Welch WJ
Am J Physiol; 1996 Oct; 271(4 Pt 2):R891-6. PubMed ID: 8897978
[TBL] [Abstract][Full Text] [Related]
14. Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR.
Li JS; Sharifi AM; Schiffrin EL
J Cardiovasc Pharmacol; 1997 Jul; 30(1):75-83. PubMed ID: 9268224
[TBL] [Abstract][Full Text] [Related]
15. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors.
Maeso R; Navarro-Cid J; Muñoz-García R; Rodrigo E; Ruilope LM; Lahera V; Cachofeiro V
Hypertension; 1996 Dec; 28(6):967-72. PubMed ID: 8952584
[TBL] [Abstract][Full Text] [Related]
16. [Effect of losartan on human platelet activation by thromboxane A2].
Guerra JI; Montón M; Rodríguez-Feo JA; Farré J; Jiménez AM; Núñez A; Gómez J; Rico L; Marcos P; Castilla C; Sánchez De Miguel L; Casado S; López-Farré A
Rev Esp Cardiol; 2000 Apr; 53(4):525-30. PubMed ID: 10758030
[TBL] [Abstract][Full Text] [Related]
17. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.
Sachinidis A; Ko Y; Weisser P; Meyer zu Brickwedde MK; Düsing R; Christian R; Wieczorek AJ; Vetter H
J Hypertens; 1993 Feb; 11(2):155-62. PubMed ID: 8385175
[TBL] [Abstract][Full Text] [Related]
18. Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide.
Maeso R; Rodrigo E; Muñoz-Garcia R; Navarro-Cid J; Ruilope LM; Lahera V; Cachofeiro V
J Hypertens; 1997 Dec; 15(12 Pt 2):1677-84. PubMed ID: 9488222
[TBL] [Abstract][Full Text] [Related]
19. Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
Li Q; Pfaffendorf M; van Zwieten PA
Fundam Clin Pharmacol; 2001 Apr; 15(2):143-50. PubMed ID: 11468024
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.
Li P; Chappell MC; Ferrario CM; Brosnihan KB
Hypertension; 1997 Jan; 29(1 Pt 2):394-400. PubMed ID: 9039133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
